Roche says sefaxersen achieved statistically significant 43.1% reduction in proteinuria in interim Phase III data
Roche said interim Phase III data showed sefaxersen achieved a statistically significant 43.1% reduction in proteinuria in people with IgA nephropathy, with no new safety signals.
1. Interim Phase III results
Roche said sefaxersen achieved a statistically significant 43.1% reduction in proteinuria in people with IgA nephropathy. Treatment effects across all prespecified subgroups were consistent with clinically meaningful reductions, and the drug was well tolerated with no new safety signals.
